President Kruska stated, “While the German medical device market is one of the largest in Europe, it is a bit slow in accepting changes. Nevertheless, the molecular diagnosis sector is currently expanding rapidly.” He explained, “As a consumer who has used Seegene’s molecular diagnosis products before, I am well aware that Seegene’s powerful and accurate multiplex technology not only saves test time and costs, but also provides a much broader range of information on pathogens per test. I am certain that demand for Seegene products will continue to grow.
?
Thus far, Seegene has gained CE-IVD certification for over 40 products, including its multiplex detection products for respiratory infections, STIs, HPVs, TB and the drug resistance detection and more.
The appointment of President Kruska is expected to allow Seegene to embark on an aggressive localization marketing strategy, based on his extensive experience with large commercial labs and profound understanding of the medical device market in Germany and other European countries.